Do analysts recommend SVA or ALMS?

Alumis has a consensus target price of $40.30, suggesting a potential upside of 80.56%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alumis 1 Sell rating(s) 1 Hold rating(s) 9 Buy rating(s) 1 Strong Buy rating(s) 2.83

Which has stronger earnings & valuation, SVA or ALMS?

Sinovac Biotech has higher revenue and earnings than Alumis. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Alumis $24.05M 118.32 -$243.32M -$1.98 N/A

Is SVA or ALMS more profitable?

Sinovac Biotech has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Sinovac Biotech's return on equity of 0.00% beat Alumis' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Alumis -2,825.70% -88.79% -70.72%

Does the media prefer SVA or ALMS?

In the previous week, Sinovac Biotech and Sinovac Biotech both had 1 articles in the media. Sinovac Biotech's average media sentiment score of 0.67 beat Alumis' score of 0.63 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alumis 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts rate IDYA or SVA?

IDEAYA Biosciences currently has a consensus target price of $50.69, indicating a potential upside of 65.81%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score IDEAYA Biosciences 1 Sell rating(s) 1 Hold rating(s) 15 Buy rating(s) 0 Strong Buy rating(s) 2.82 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has preferable valuation & earnings, IDYA or SVA?

Sinovac Biotech has higher revenue and earnings than IDEAYA Biosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio IDEAYA Biosciences $218.71M 12.28 -$113.70M -$1.60 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is IDYA or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat IDEAYA Biosciences' return on equity. Company Net Margins Return on Equity Return on Assets IDEAYA Biosciences N/A -14.24% -13.09% Sinovac Biotech N/A N/A N/A

Does the media refer more to IDYA or SVA?

In the previous week, IDEAYA Biosciences had 7 more articles in the media than Sinovac Biotech. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.67 beat IDEAYA Biosciences' score of 0.33 indicating that Sinovac Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment IDEAYA Biosciences 1 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SVA or CLDX?

Celldex Therapeutics has a consensus price target of $49.30, indicating a potential upside of 52.54%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Celldex Therapeutics 1 Sell rating(s) 1 Hold rating(s) 8 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has better earnings & valuation, SVA or CLDX?

Sinovac Biotech has higher revenue and earnings than Celldex Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Celldex Therapeutics $1.54M 1,647.27 -$258.76M -$4.26 N/A

Is SVA or CLDX more profitable?

Sinovac Biotech's return on equity of 0.00% beat Celldex Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Sinovac Biotech N/A N/A N/A Celldex Therapeutics N/A -50.72% -46.59%

Does the media refer more to SVA or CLDX?

In the previous week, Celldex Therapeutics had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Celldex Therapeutics and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.63 indicating that Sinovac Biotech is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Celldex Therapeutics 0 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend VERA or SVA?

Vera Therapeutics currently has a consensus target price of $78.00, suggesting a potential upside of 131.66%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Vera Therapeutics is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vera Therapeutics 1 Sell rating(s) 1 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 2.75 Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00

Which has stronger earnings and valuation, VERA or SVA?

Sinovac Biotech has higher revenue and earnings than Vera Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vera Therapeutics N/A N/A -$299.61M -$5.54 N/A Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A

Is VERA or SVA more profitable?

Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Vera Therapeutics N/A -74.86% -60.18% Sinovac Biotech N/A N/A N/A

Does the media favor VERA or SVA?

In the previous week, Vera Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Vera Therapeutics and 1 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 0.84 beat Sinovac Biotech's score of 0.67 indicating that Vera Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Vera Therapeutics 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Do analysts recommend SVA or RARE?

Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 139.69%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Sinovac Biotech. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Sinovac Biotech 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Ultragenyx Pharmaceutical 1 Sell rating(s) 2 Hold rating(s) 13 Buy rating(s) 1 Strong Buy rating(s) 2.82

Which has preferable earnings & valuation, SVA or RARE?

Sinovac Biotech has higher earnings, but lower revenue than Ultragenyx Pharmaceutical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sinovac Biotech $386.01M 1.67 -$59.68M N/A N/A Ultragenyx Pharmaceutical $673M 3.64 -$575M -$6.11 N/A

Does the media prefer SVA or RARE?

In the previous week, Ultragenyx Pharmaceutical had 9 more articles in the media than Sinovac Biotech. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 1 mentions for Sinovac Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.00 beat Sinovac Biotech's score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sinovac Biotech 0 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Ultragenyx Pharmaceutical 7 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Sinovac Biotech (SVA) Competitors

$6.47 0.00 (0.00%)

As of 06/15/2026

Compare

SVA vs. ALMS, IDYA, CLDX, VERA, and RARE

Should you buy Sinovac Biotech stock or one of its competitors? MarketBeat compares Sinovac Biotech with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Sinovac Biotech include Alumis (ALMS), IDEAYA Biosciences (IDYA), Celldex Therapeutics (CLDX), Vera Therapeutics (VERA), and Ultragenyx Pharmaceutical (RARE). These companies are all part of the "med - biomed/gene" industry.

How does Sinovac Biotech compare to Alumis?

Sinovac Biotech (NASDAQ:SVA) and Alumis (NASDAQ:ALMS) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their media sentiment, risk, analyst recommendations, dividends, institutional ownership, valuation, earnings and profitability.

Alumis has a consensus target price of $40.30, suggesting a potential upside of 80.56%. Given Alumis' stronger consensus rating and higher probable upside, analysts clearly believe Alumis is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alumis	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.83

Sinovac Biotech has higher revenue and earnings than Alumis.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Alumis	$24.05M	118.32	-$243.32M	-$1.98	N/A

Sinovac Biotech has a beta of 0.73, meaning that its share price is 27% less volatile than the broader market. Comparatively, Alumis has a beta of -0.56, meaning that its share price is 156% less volatile than the broader market.

In the previous week, Sinovac Biotech and Sinovac Biotech both had 1 articles in the media. Sinovac Biotech's average media sentiment score of 0.67 beat Alumis' score of 0.63 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alumis	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sinovac Biotech has a net margin of 0.00% compared to Alumis' net margin of -2,825.70%. Sinovac Biotech's return on equity of 0.00% beat Alumis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Alumis	-2,825.70%	-88.79%	-70.72%

Summary

Sinovac Biotech beats Alumis on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to IDEAYA Biosciences?

IDEAYA Biosciences (NASDAQ:IDYA) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations.

In the previous week, IDEAYA Biosciences had 7 more articles in the media than Sinovac Biotech. MarketBeat recorded 8 mentions for IDEAYA Biosciences and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.67 beat IDEAYA Biosciences' score of 0.33 indicating that Sinovac Biotech is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
IDEAYA Biosciences	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

IDEAYA Biosciences has a beta of -0.05, suggesting that its share price is 105% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat IDEAYA Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
IDEAYA Biosciences	N/A	-14.24%	-13.09%
Sinovac Biotech	N/A	N/A	N/A

IDEAYA Biosciences currently has a consensus target price of $50.69, indicating a potential upside of 65.81%. Given IDEAYA Biosciences' stronger consensus rating and higher possible upside, research analysts plainly believe IDEAYA Biosciences is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
IDEAYA Biosciences	1 Sell rating(s)	1 Hold rating(s)	15 Buy rating(s)	0 Strong Buy rating(s)	2.82
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Sinovac Biotech has higher revenue and earnings than IDEAYA Biosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
IDEAYA Biosciences	$218.71M	12.28	-$113.70M	-$1.60	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

98.3% of IDEAYA Biosciences shares are owned by institutional investors. 4.7% of IDEAYA Biosciences shares are owned by insiders. Comparatively, 12.8% of Sinovac Biotech shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Sinovac Biotech beats IDEAYA Biosciences on 7 of the 13 factors compared between the two stocks.

How does Sinovac Biotech compare to Celldex Therapeutics?

Sinovac Biotech (NASDAQ:SVA) and Celldex Therapeutics (NASDAQ:CLDX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, media sentiment, institutional ownership, risk, dividends, analyst recommendations, earnings and valuation.

Celldex Therapeutics has a consensus price target of $49.30, indicating a potential upside of 52.54%. Given Celldex Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Celldex Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Celldex Therapeutics	1 Sell rating(s)	1 Hold rating(s)	8 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Celldex Therapeutics had 5 more articles in the media than Sinovac Biotech. MarketBeat recorded 6 mentions for Celldex Therapeutics and 1 mentions for Sinovac Biotech. Sinovac Biotech's average media sentiment score of 0.67 beat Celldex Therapeutics' score of 0.63 indicating that Sinovac Biotech is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Celldex Therapeutics	0 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sinovac Biotech has higher revenue and earnings than Celldex Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Celldex Therapeutics	$1.54M	1,647.27	-$258.76M	-$4.26	N/A

Sinovac Biotech has a beta of 0.73, indicating that its share price is 27% less volatile than the broader market. Comparatively, Celldex Therapeutics has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market.

Sinovac Biotech's return on equity of 0.00% beat Celldex Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Celldex Therapeutics	N/A	-50.72%	-46.59%

Summary

Celldex Therapeutics beats Sinovac Biotech on 7 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Vera Therapeutics?

Vera Therapeutics (NASDAQ:VERA) and Sinovac Biotech (NASDAQ:SVA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

Sinovac Biotech has higher revenue and earnings than Vera Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vera Therapeutics	N/A	N/A	-$299.61M	-$5.54	N/A
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A

Sinovac Biotech's return on equity of 0.00% beat Vera Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vera Therapeutics	N/A	-74.86%	-60.18%
Sinovac Biotech	N/A	N/A	N/A

Vera Therapeutics currently has a consensus target price of $78.00, suggesting a potential upside of 131.66%. Given Vera Therapeutics' stronger consensus rating and higher possible upside, research analysts clearly believe Vera Therapeutics is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vera Therapeutics	1 Sell rating(s)	1 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.75
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Vera Therapeutics has a beta of 0.93, meaning that its stock price is 7% less volatile than the broader market. Comparatively, Sinovac Biotech has a beta of 0.73, meaning that its stock price is 27% less volatile than the broader market.

99.2% of Vera Therapeutics shares are held by institutional investors. 15.9% of Vera Therapeutics shares are held by company insiders. Comparatively, 12.8% of Sinovac Biotech shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

In the previous week, Vera Therapeutics had 1 more articles in the media than Sinovac Biotech. MarketBeat recorded 2 mentions for Vera Therapeutics and 1 mentions for Sinovac Biotech. Vera Therapeutics' average media sentiment score of 0.84 beat Sinovac Biotech's score of 0.67 indicating that Vera Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Vera Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Vera Therapeutics beats Sinovac Biotech on 8 of the 12 factors compared between the two stocks.

How does Sinovac Biotech compare to Ultragenyx Pharmaceutical?

Sinovac Biotech (NASDAQ:SVA) and Ultragenyx Pharmaceutical (NASDAQ:RARE) are both medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings.

97.7% of Ultragenyx Pharmaceutical shares are owned by institutional investors. 12.8% of Sinovac Biotech shares are owned by company insiders. Comparatively, 5.2% of Ultragenyx Pharmaceutical shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Sinovac Biotech has higher earnings, but lower revenue than Ultragenyx Pharmaceutical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sinovac Biotech	$386.01M	1.67	-$59.68M	N/A	N/A
Ultragenyx Pharmaceutical	$673M	3.64	-$575M	-$6.11	N/A

Ultragenyx Pharmaceutical has a consensus price target of $59.56, suggesting a potential upside of 139.69%. Given Ultragenyx Pharmaceutical's stronger consensus rating and higher probable upside, analysts clearly believe Ultragenyx Pharmaceutical is more favorable than Sinovac Biotech.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sinovac Biotech	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Ultragenyx Pharmaceutical	1 Sell rating(s)	2 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.82

In the previous week, Ultragenyx Pharmaceutical had 9 more articles in the media than Sinovac Biotech. MarketBeat recorded 10 mentions for Ultragenyx Pharmaceutical and 1 mentions for Sinovac Biotech. Ultragenyx Pharmaceutical's average media sentiment score of 1.00 beat Sinovac Biotech's score of 0.67 indicating that Ultragenyx Pharmaceutical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sinovac Biotech	0 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Ultragenyx Pharmaceutical	7 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Sinovac Biotech has a beta of 0.73, indicating that its stock price is 27% less volatile than the broader market. Comparatively, Ultragenyx Pharmaceutical has a beta of 0.37, indicating that its stock price is 63% less volatile than the broader market.

Sinovac Biotech has a net margin of 0.00% compared to Ultragenyx Pharmaceutical's net margin of -91.03%. Sinovac Biotech's return on equity of 0.00% beat Ultragenyx Pharmaceutical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sinovac Biotech	N/A	N/A	N/A
Ultragenyx Pharmaceutical	-91.03%	-1,024.42%	-45.78%

Summary

Ultragenyx Pharmaceutical beats Sinovac Biotech on 9 of the 15 factors compared between the two stocks.

Get Sinovac Biotech News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SVA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SVA vs. The Competition

Export

Metric	Sinovac Biotech	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$644.66M	$3.40B	$6.50B	$12.35B
Dividend Yield	N/A	2.28%	2.67%	5.67%
P/E Ratio	N/A	19.31	24.11	24.25
Price / Sales	1.67	307.67	517.95	108.09
Price / Cash	11.89	125.07	44.13	56.68
Price / Book	0.07	8.01	10.52	6.69
Net Income	-$59.68M	$23.89M	$3.56B	$337.12M
7 Day Performance	N/A	0.88%	0.18%	1.78%
1 Month Performance	N/A	-0.39%	1.53%	3.64%
1 Year Performance	N/A	43.71%	24.25%	28.19%

Sinovac Biotech Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SVA Sinovac Biotech	0.7215 of 5 stars	$6.47 flat	N/A	N/A	$644.66M	$386.01M	N/A	2,643	News Coverage High Trading Volume
ALMS Alumis	3.0336 of 5 stars	$20.06 +0.2%	$40.30 +100.9%	+632.5%	$2.55B	$24.05M	N/A	N/A	Positive News
IDYA IDEAYA Biosciences	2.7867 of 5 stars	$27.60 -1.7%	$50.69 +83.7%	+36.3%	$2.47B	$218.71M	N/A	80	Analyst Upgrade
CLDX Celldex Therapeutics	2.148 of 5 stars	$29.35 -0.8%	$49.30 +68.0%	+51.1%	$2.32B	$1.54M	N/A	150	News Coverage Analyst Forecast
VERA Vera Therapeutics	2.6954 of 5 stars	$31.62 -0.6%	$78.00 +146.7%	+50.6%	$2.28B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SVA) was last updated on 6/16/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sinovac Biotech (SVA) Competitors

SVA vs. ALMS, IDYA, CLDX, VERA, and RARE

How does Sinovac Biotech compare to Alumis?

Summary

How does Sinovac Biotech compare to IDEAYA Biosciences?

Summary

How does Sinovac Biotech compare to Celldex Therapeutics?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Summary

How does Sinovac Biotech compare to Ultragenyx Pharmaceutical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sinovac Biotech (SVA) Competitors

SVA vs. ALMS, IDYA, CLDX, VERA, and RARE

How does Sinovac Biotech compare to Alumis?

Do analysts recommend SVA or ALMS?

Which has stronger earnings & valuation, SVA or ALMS?

Which has more volatility & risk, SVA or ALMS?

Does the media prefer SVA or ALMS?

Is SVA or ALMS more profitable?

Summary

How does Sinovac Biotech compare to IDEAYA Biosciences?

Does the media refer more to IDYA or SVA?

Which has more volatility and risk, IDYA or SVA?

Is IDYA or SVA more profitable?

Do analysts rate IDYA or SVA?

Which has preferable valuation & earnings, IDYA or SVA?

Do insiders and institutionals believe in IDYA or SVA?

Summary

How does Sinovac Biotech compare to Celldex Therapeutics?

Do analysts recommend SVA or CLDX?

Does the media refer more to SVA or CLDX?

Which has better earnings & valuation, SVA or CLDX?

Which has more risk & volatility, SVA or CLDX?

Is SVA or CLDX more profitable?

Summary

How does Sinovac Biotech compare to Vera Therapeutics?

Which has stronger earnings and valuation, VERA or SVA?

Is VERA or SVA more profitable?

Do analysts recommend VERA or SVA?

Which has more risk & volatility, VERA or SVA?

Do institutionals and insiders have more ownership in VERA or SVA?

Does the media favor VERA or SVA?

Summary

How does Sinovac Biotech compare to Ultragenyx Pharmaceutical?

Do insiders and institutionals hold more shares of SVA or RARE?

Which has preferable earnings & valuation, SVA or RARE?

Do analysts recommend SVA or RARE?

Does the media prefer SVA or RARE?

Which has more volatility & risk, SVA or RARE?

Is SVA or RARE more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SVA vs. The Competition

Sinovac Biotech Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools